NCT03833128 - A Phase 1b Study of the Safety of REN001 in Patients With Fatty Acid Oxidation Disorders | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 4, 2019

Primary Completion Date

January 24, 2022

Study Completion Date

March 21, 2022

Conditions

Fatty Acid Oxidation Disorders

Interventions

DRUG

Low Dose REN001

Oral

DRUG

High Dose REN001

Oral

Trial Locations (7)

15224

Children's Hospital of Pittsburgh, Pittsburgh

80045

Children's Hospital Colorado, Aurora

84108

Division of Medical Genetics, University Utah, Salt Lake City

92380

Neurology department, Raymond-Poincaré Teaching Hospital, Nord/Est/Ile de France Neuromuscular Reference Center, Garches

97239

Oregon Health and Science University, Portland

75390-8591

UT Southwestern Medical Center, Dallas

CP 28041

Servicio de Neurología - Unidad de Neuromuscular Centro de Referencia Nacional de Enfermedades Neuromusculares raras Instituto de Investigación i+12, Madrid

All Listed Sponsors

lead

Reneo Pharma Ltd

INDUSTRY